DOCSLIB.ORG

Section 4.5 Genotoxicity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Section 4.5 Genotoxicity Section 4.5 Genotoxicity Second edition (2020) Hazard Identification and Characterization CONTENTS LIST OF ABBREVIATIONS 4-3 LIST OF CONTRIBUTORS 4-6 4.5 Genotoxicity 4-8 4.5.1 Introduction 4-8 Risk analysis context and problem formulation 4-10 Decision-tree for assessing the mutagenicity of substances that can be found in food 4-12 4.5.2 Tests for genotoxicity 4-19 Bacterial mutagenicity 4-23 In vitro mammalian cell mutagenicity 4-23 (a) Forward gene mutation tests using the Tk gene 4-24 (b) Forward gene mutation tests using the Hprt and Xprt genes 4-24 In vivo mammalian cell mutagenicity 4-25 (a) Somatic cell assays 4-25 (b) Germ cell assays 4-26 In vitro chromosomal damage assays 4-27 (a) Chromosomal aberration assay 4-27 (b) Micronucleus (MN) assay 4-28 (c) TK assay in mammalian cells 4-28 In vivo chromosomal damage assays 4-29 (a) Chromosomal aberration assay 4-29 (b) Micronucleus (MN) assay 4-29 In vitro DNA damage/repair assays 4-30 In vivo DNA damage/repair assays 4-30 This text updates section 4.5 of Chapter 4, Hazard Identification and Characterization: Toxicological and Human Studies, of Environmental Health Criteria 240 (EHC 240), which was originally published in 2009. It was developed through an expert consultation and further advanced following comments received through a public consultation in December 2019. For abbreviations used in the text, the reader may refer to the list of abbreviations at the front of this section. Definitions of select terms may be found in the glossary in Annex 1 of EHC 240 (http://www.inchem.org/ documents/ehc/ehc/ehc240_annex1.pdf). 4-1 EHC 240: Principles for Risk Assessment of Chemicals in Food (a) Comet (single-cell gel electrophoresis) assay 4-30 (b) DNA adduct assays 4-32 (c) Unscheduled DNA synthesis (UDS) assay in mammalian liver 4-32 4.5.3 Identification of relevant studies 4-33 4.5.4 Interpretation of test results 4-34 Presentation and categorization of results 4-35 (a) Assessing whether results of an assay are positive, negative or equivocal for genotoxicity 4-37 (b) Assessing data quality 4-38 Weighting and integration of results 4-46 Adequacy of the genotoxicity database 4-49 Mutagenic mode of action and adverse outcomes 4-50 Integration of carcinogenicity and mutagenicity 4-53 4.5.5 Approaches for evaluating data-poor substances 4-56 In silico approaches 4-56 (a) Available tools (QSARs, SARs/ structural alerts) for mutagenicity 4-57 (b) Confidence in approaches 4-57 (c) Mutagenicity assessment 4-63 Threshold of toxicological concern (TTC) 4-65 Grouping and read-across approaches 4-68 4.5.6 Considerations for specific compounds 4-71 Mixtures 4-71 Flavouring agents 4-73 Metabolites in crops/food-producing animals, degradation products and impurities 4-75 Secondary metabolites in enzyme preparations 4-79 4.5.7 Recent developments and future directions 4-81 Novel in vivo genotoxicity approaches 4-82 Novel in vitro genotoxicity approaches 4-82 Adverse outcome pathways for mutagenicity 4-90 Quantitative approaches for safety assessment 4-92 4.5.8 References 4-93 4-2 Hazard Identification and Characterization List of abbreviations ACD Advanced Chemistry Development, Inc. ADI acceptable daily intake AOP adverse outcome pathway ARfD acute reference dose ATSDR Agency for Toxic Substances and Disease Registry (USA) BMD benchmark dose CAS Chemical Abstracts Service CCRIS Chemical Carcinogenesis Research Information System CEBS Chemical Effects in Biological Systems Cefic European Chemical Industry Council CHL Chinese hamster lung CHO Chinese hamster ovary CTD Comparative Toxicogenomics Database DDI DNA damage–inducing DNA deoxyribonucleic acid ECHA European Chemicals Agency EFSA European Food Safety Authority EHC Environmental Health Criteria EU European Union EURL ECVAM European Union Reference Laboratory for alternatives to animal testing FAO Food and Agriculture Organization of the United Nations GENE-TOX Genetic Toxicology Data Bank GLP Good Laboratory Practice gpt glutamic–pyruvic transaminase HBGV health-based guidance value Hprt/HPRT hypoxanthine–guanine phosphoribosyl transferase HTRF Homogeneous Time-Resolved Fluorescence IATA Integrated Approaches to Testing and Assessment ICH International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use INCHEM Internationally Peer Reviewed Chemical Safety Information IPCS International Programme on Chemical Safety IRIS Integrated Risk Information System (USA) ISS Istituto Superiore di Sanità (Italy) 4-3 EHC 240: Principles for Risk Assessment of Chemicals in Food ISSMIC Istituto Superiore di Sanità database on in vivo mutagenicity (micronucleus test) ISSSTY Istituto Superiore di Sanità database on in vitro mutagenicity in Salmonella typhimurium (Ames test) JECDB Japanese Existing Chemical Data Base JECFA Joint FAO/WHO Expert Committee on Food Additives JMPR Joint FAO/WHO Meeting on Pesticide Residues LRI Long-range Research Initiative MAK maximum workplace concentration MN micronucleus/micronuclei MOA mode of action MOE margin of exposure NGS next-generation DNA sequencing NIHS National Institute of Health Sciences (Japan) NOAEL no-observed-adverse-effect level NOGEL no-observed-genotoxic-effect level NTP National Toxicology Program (USA) OECD Organisation for Economic Co-operation and Development PAH polycyclic aromatic hydrocarbon PCR polymerase chain reaction Pig-a phosphatidylinositol glycan complementation group A qPCR quantitative polymerase chain reaction QSAR quantitative structure–activity relationship REACH Registration, Evaluation, Authorisation and Restriction of Chemicals RNA ribonucleic acid RT-qPCR reverse transcription quantitative polymerase chain reaction S9 9000 × g supernatant fraction from rat liver homogenate SAR structure–activity relationship SciRAP Science in Risk Assessment and Policy SYRCLE Systematic Review Centre for Laboratory Animal Experimentation Td threshold dose TDI tolerable daily intake T.E.S.T. Toxicity Estimation Software Tool TG test guideline; thioguanine TIMES tissue metabolism simulator 4-4 Hazard Identification and Characterization Tk/TK thymidine kinase ToxRTool Toxicological data Reliability Assessment Tool TTC threshold of toxicological concern UDS unscheduled DNA synthesis USA United States of America USEPA United States Environmental Protection Agency USFDA United States Food and Drug Administration WHO World Health Organization WOE weight of evidence Xprt/XPRT xanthine–guanine phosphoribosyl transferase 4-5 EHC 240: Principles for Risk Assessment of Chemicals in Food List of contributors Dr Virunya Bhat PAHO/WHO Collaborating Centre on Food Safety, Water Quality and Indoor Environment, NSF International, Ann Arbor, Michigan, United States of America (USA) Emeritus Professor Alan R. Boobis (co-lead author) National Heart & Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom Dr Riccardo Crebelli Istituto Superiore di Sanità, Rome, Italy Dr Nathalie Delrue Test Guidelines Programme, Environment, Health and Safety Division, Environment Directorate, Organisation for Economic Co-operation and Development, Paris, France Professor David Eastmond (co-lead author) Department of Molecular, Cell, and Systems Biology, University of California, Riverside, California, USA Dr Susan Page Felter Mason, Ohio, USA Dr Rainer Guertler Federal Institute for Risk Assessment (BfR), Berlin, Germany Professor Andrea Hartwig Karlsruhe, Germany Dr Frank Le Curieux European Chemicals Agency, Helsinki, Finland Professor Angelo Moretto Department of Biomedical and Clinical Sciences, University of Milan, and International Centre for Pesticides and Health Risk Prevention, Luigi Sacco Hospital, Milan, Italy Professor Pasquale Mosesso Department of Ecological and Biological Sciences, Università degli Studi della Tuscia, Viterbo, Italy Dr Utz Mueller Australian Pesticides and Veterinary Medicines Authority, Kingston, Australian Capital Territory, Australia 4-6 Hazard Identification and Characterization Dr Takehiko Nohmi Biological Safety Research Center, National Institute of Health Sciences, Kamiyoga, Setagaya-ku, Tokyo, Japan Dr Grace Patlewicz National Center for Computational Toxicology, United States Environmental Protection Agency, Durham, North Carolina, USA Professor David H. Phillips King’s College London, London, United Kingdom Dr Andrea Richarz Institute for Health and Consumer Protection, Joint Research Centre, European Commission, Ispra, Italy Dr Raymond R. Tice National Institutes of Environmental Health Sciences, Research Triangle Park, North Carolina, USA Dr Paul A. White Genetic Toxicology Group, Environmental Health Sciences & Research Bureau, Environmental & Radiation Health Sciences Directorate, Healthy Environments & Consumer Safety Branch, Health Canada, Ottawa, Ontario, Canada Dr Kristine L. Witt National Institutes of Environmental Health Sciences, Research Triangle Park, North Carolina, USA 4-7 EHC 240: Principles for Risk Assessment of Chemicals in Food 4.5 Genotoxicity 4.5.1 Introduction The study of toxic effects on the inherited genetic material in cells originated with the experiments of Muller (1927), who observed “artificial transmutation of the gene” by ionizing radiation in the fruit fly, Drosophila melanogaster. Chemically induced mutation also has a long history, with the first scientific publication, using Muller’s fruit fly model, describing mutations arising from exposure to sulfur mustard (Auerbach, Robson & Carr, 1947). A key event stimulating the development and validation of genetic toxicity
Load more

Recommended publications
  • Comet Assay Modifications for Its Application in Food Safety
    Facultad de Farmacia y Nutrición Comet assay modifications for its application in food safety Modificaciones del ensayo del cometa para su aplicación en seguridad alimentaria José Manuel Enciso Gadea Facultad de Farmacia y Nutrición El presente trabajo de investigación titulado: Comet assay modifications for its application in food safety Modificaciones del ensayo del cometa para su aplicación en seguridad alimentaria que presenta D. José Manuel Enciso Gadea para aspirar al grado de Doctor por la Universidad de Navarra en el Programa de Doctorado en Alimentación, Fisiología y Salud, ha sido realizado en el Departamento de Farmacología y Toxicología de la Facultad de Farmacia y Nutrición, bajo la dirección de la Dra. Adela López de Cerain Salsamendi y la co-dirección de la Dra. Amaya Azqueta Oscoz y la Dra. Ariane Vettorazzi Armental. Pamplona, 8 de febrero de 2018 Dra. Amaya Azqueta Oscoz Dra. Ariane Vettorazzi Armental Dra. Adela López de Cerain Salsamendi This work received financial support from: The “Asociación de Amigos” of the University of Navarra (Predoctoral grant). Ministry of Economy, Industry and Competitiveness (Spain). BIOGENSA Project: “Aplicación de una nueva estrategia de evaluación de genotoxicidad en ingredientes funcionales y en frituras de restauración colectiva” (AGL2015-70640-R) University of Navarra (PIUNA). Project: “Efecto cancerígeno de la ocratoxina A: influencia del sexo en el mecanismo de acción” [PIUNA 2012]. Acknowledgements / Agradecimientos Con estas breves palabras deseo expresar mi más sincero agradecimiento a todas aquellas personas que, de una manera u otra, me han ayudado a que esta tesis doctoral sea una realidad. En primer lugar, a la Universidad de Navarra, por haberme formado tanto en el plano intelectual como en el humano, y la Asociación de Amigos de la misma, por haberme dotado con los medios económicos para la consecución de este proyecto.
    [Show full text]
  • Detailed Review Paper on Retinoid Pathway Signalling
    1 1 Detailed Review Paper on Retinoid Pathway Signalling 2 December 2020 3 2 4 Foreword 5 1. Project 4.97 to develop a Detailed Review Paper (DRP) on the Retinoid System 6 was added to the Test Guidelines Programme work plan in 2015. The project was 7 originally proposed by Sweden and the European Commission later joined the project as 8 a co-lead. In 2019, the OECD Secretariat was added to coordinate input from expert 9 consultants. The initial objectives of the project were to: 10 draft a review of the biology of retinoid signalling pathway, 11 describe retinoid-mediated effects on various organ systems, 12 identify relevant retinoid in vitro and ex vivo assays that measure mechanistic 13 effects of chemicals for development, and 14 Identify in vivo endpoints that could be added to existing test guidelines to 15 identify chemical effects on retinoid pathway signalling. 16 2. This DRP is intended to expand the recommendations for the retinoid pathway 17 included in the OECD Detailed Review Paper on the State of the Science on Novel In 18 vitro and In vivo Screening and Testing Methods and Endpoints for Evaluating 19 Endocrine Disruptors (DRP No 178). The retinoid signalling pathway was one of seven 20 endocrine pathways considered to be susceptible to environmental endocrine disruption 21 and for which relevant endpoints could be measured in new or existing OECD Test 22 Guidelines for evaluating endocrine disruption. Due to the complexity of retinoid 23 signalling across multiple organ systems, this effort was foreseen as a multi-step process.
    [Show full text]
  • Krifka Publikation Glanzlicht 09
    This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues. Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited. In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier’s archiving and manuscript policies are encouraged to visit: http://www.elsevier.com/copyright Author's personal copy Biomaterials 32 (2011) 1787e1795 Contents lists available at ScienceDirect Biomaterials journal homepage: www.elsevier.com/locate/biomaterials Activation of stress-regulated transcription factors by triethylene glycol dimethacrylate monomer Stephanie Krifka a, Christine Petzel a, Carola Bolay a, Karl-Anton Hiller a, Gianrico Spagnuolo b, Gottfried Schmalz a, Helmut Schweikl a,* a Department of Operative Dentistry and Periodontology, University of Regensburg, D-93042 Regensburg, Germany b Department of Oral and Maxillofacial Sciences, University of Naples “Federico II”, Italy article info abstract Article history: Triethylene glycol dimethacrylate (TEGDMA) is a resin monomer available for short exposure scenarios of Received 22 October 2010 oral tissues due to incomplete polymerization processes of dental composite materials. The generation of Accepted 14 November 2010 reactive oxygen species (ROS) in the presence of resin monomers is discussed as a common mechanism Available online 10 December 2010 underlying cellular reactions as diverse as disturbed responses of the innate immune system, inhibition of dentin mineralization processes, genotoxicity and a delayed cell cycle.
    [Show full text]
  • Mice Exposed to N-Ethyl-N-Nitrosourea T
    Proc. Nati. Acad. Sci. USA Vol. 89, pp. 7866-7870, September 1992 Genetics Mutational spectrum at the Hprt locus in splenic T cells of B6C3F1 mice exposed to N-ethyl-N-nitrosourea T. R. SKOPEK*tt, V. E. WALKER*, J. E. COCHRANEt, T. R. CRAFTt, AND N. F. CARIELLO* *Department of Pathology and tDepartment of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 Communicated by Kenneth M. Brinkhous, May 26, 1992 ABSTRACT We have determined the mutational spectrum quences for analysis. DGGE is based on the fact that the of N-ethyl-N-nitrosourea (ENU) in exon 3 of the hypoxanthine electrophoretic mobility of a DNA molecule in a polyacryl- guanine) phosphoribosyltransferase gene (Hprt) in splenic T amide gel is considerably reduced as the molecule becomes cells following in vivo exposure ofmale B6C3F1 mice (5-7 weeks partially melted (denatured). Mismatched heteroduplexes old) to ENU. Hpir mutants were isolated by culturing splenic formed by annealing wild-type and mutant DNA sequences T cells in microtiter dishes containing medium supplemented are always less stable than the corresponding perfectly base- with interleukin 2, concanavalin A, and 6-thiouanine. DNA paired homoduplexes and consequently melt at a lower was extracted from 6-thoa ne-sistant colonies and ampli- concentration of denaturant. Therefore, any mutant/wild- fied by the polymerase chain reaction (PCR) using primers type heteroduplex will always travel a shorter distance rel- flanking Hprt exon 3. Identification of mutant sequences and ative to wild-type homoduplexes in a gel containing a dient purification of mutant DNA from contaminating wild-type Hprt ofdenaturant.
    [Show full text]
  • Principles and Methods for the Risk Assessment of Chemicals in Food
    WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTE EHC240: Principles and Methods for the Risk Assessment of Chemicals in Food SUBCHAPTER 4.5. Genotoxicity Draft 12/12/2019 Deadline for comments 31/01/2020 The contents of this restricted document may not be divulged to persons other than those to whom it has been originally addressed. It may not be further distributed nor reproduced in any manner and should not be referenced in bibliographical matter or cited. Le contenu du présent document à distribution restreinte ne doit pas être divulgué à des personnes autres que celles à qui il était initialement destiné. Il ne saurait faire l’objet d’une redistribution ou d’une reproduction quelconque et ne doit pas figurer dans une bibliographie ou être cité. Hazard Identification and Characterization 4.5 Genotoxicity ................................................................................. 3 4.5.1 Introduction ........................................................................ 3 4.5.1.1 Risk Analysis Context and Problem Formulation .. 5 4.5.2 Tests for genetic toxicity ............................................... 14 4.5.2.2 Bacterial mutagenicity ............................................. 18 4.5.2.2 In vitro mammalian cell mutagenicity .................... 18 4.5.2.3 In vivo mammalian cell mutagenicity ..................... 20 4.5.2.4 In vitro chromosomal damage assays .................. 22 4.5.2.5 In vivo chromosomal damage assays ................... 23 4.5.2.6 In vitro DNA damage/repair assays ....................... 24 4.5.2.7 In vivo DNA damage/repair assays ....................... 25 4.5.3 Interpretation of test results ......................................... 26 4.5.3.1 Identification of relevant studies............................. 27 4.5.3.2 Presentation and categorization of results ........... 30 4.5.3.3 Weighting and integration of results .....................
    [Show full text]
  • Protocol 4253-096-K
    IFU0132 Rev 1 Status: RELEASED printed 12/8/2016 2:11:21 PM by Trevigen Document Control Instructions For Research Use Only. Not For Use In Diagnostic Procedures ® CometAssay 96 Reagent Kit for Higher Throughput Single Cell Gel Electrophoresis Assay (96-well) Catalog # 4253-096-K IFU0132 Rev 1 Status: RELEASED printed 12/8/2016 2:11:21 PM by Trevigen Document Control ® CometAssay 96 Reagent Kit for Higher Throughput Single Cell Gel Electrophoresis Assay (96-well) Catalog # 4253-096-K Table of Contents Page Number I. Background 1 II. Precautions and Limitations 1 III. Materials Supplied 2 IV. Materials Required But Not Supplied 2 V. Reagent Preparation 2 VI. Sample Preparation and Storage 4 VII. Assay Protocol 6 VIII. Data Analysis 7 IX. References 9 X. Related Products Available From Trevigen 10 XI. Appendices 12 XII. Troubleshooting Guide 13 © 2012 Trevigen, Inc. All rights reserved. Trevigen and CometAssay are registered trademarks, and CometSlide and FLARE are trademarks of Trevigen, Inc. i IFU0132 Rev 1 Status: RELEASED printed 12/8/2016 2:11:21 PM by Trevigen Document Control I. Background Trevigen’s CometAssay®, or single cell gel electrophoresis assay, provides a simple and effective method for evaluating DNA damage in cells. The principle of the assay is based upon the ability of denatured, cleaved DNA fragments to migrate out of the nucleoid under the influence of an electric field, whereas undamaged DNA migrates slower and remains within the confines of the nucleoid when a current is applied. Evaluation of the DNA “comet” tail shape and migration pattern allows for assessment of DNA damage.
    [Show full text]
  • Application of the Comet Assay in Erythrocytes of Oreochromis Niloticus (Pisces): a Methodological Comparison
    Genetics and Molecular Biology, 32, 1, 155-158 (2009) Copyright © 2009, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Short Communication Application of the comet assay in erythrocytes of Oreochromis niloticus (Pisces): A methodological comparison Cintya A. Christofoletti1, José Augusto O. David2 and Carmem S. Fontanetti1 1Departamento de Biologia, Instituto de Biociências, Universidade Estadual Paulista “Júlio de Mesquita Filho”, Rio Claro, SP, Brazil. 2Departamento de Genética, Instituto de Biociências, Universidade Federal do Pará, Belém, PA, Brazil. Abstract The present study applied the comet assay to erythrocytes of Oreochromis niloticus with the aim of improving proto- cols to detect DNA damage in these cells, by using two distinct pHs (pH = 12.1 and pH > 13) and evaluating whether there is a correspondence between silver and ethidium bromide staining. Comets were visually examined and, the frequency of cells with and without damage was obtained, as well as the distribution of classes and scores. By using the Kruskal-Wallis test, our results revealed that pH 12.1 is more effective, although both pHs can be used. Our find- ings also suggest that silver staining can substitute ethidium bromide, an expensive and highly toxic stain that re- quires specific equipment for examination. Key words: comet assay, ethidium bromide, silver staining, tilapia. Received: April 2, 2008; Accepted: September 5, 2008. The development of new methodologies and the ap- sensitivity of the blood cells of these animals to genotoxic plication of more sensitive assays to detect genotoxicity in effects (Padrangi et al., 1995; Belpaeme et al., 1998; Gon- different samples have been the subject of several scientific tijo et al., 2003).
    [Show full text]
  • DRAFT OECD GUIDELINE for the TESTING of CHEMICALS in Vivo
    DRAFT OECD GUIDELINE FOR THE TESTING OF CHEMICALS In vivo Mammalian Alkaline Comet Assay INTRODUCTION 1. The alkaline Comet (single cell gel electrophoresis) assay is used for the detection of primary DNA damage induced in isolated cells or nuclei from multiple tissues of animals, usually rodents. 2. The purpose of the Comet assay is to identify substances that cause DNA damage. Under alkaline conditions, the Comet assay can detect single and double stranded breaks, resulting, for example, from direct interactions with DNA, alkali labile sites or as a consequence of incomplete excision repair. Under certain modified conditions the assay can detect DNA-DNA and DNA-protein crosslinking, and oxidized bases. The Comet assay has been reviewed and recommendations have been published by various expert groups (1) (2) (3) (4) (5) (6) (7) (8) (9) (10). 3. A formal validation of the in vivo rodent Comet assay was recently (2006-2012) coordinated by the Japanese Center for the Validation of Alternative Methods (JaCVAM), in conjunction with the European Centre for the Validation of Alternative Methods (ECVAM) and the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)(11). This Test Guideline includes the recommended use and limitations of the Comet assay, and is based on the Comet assay method protocol version 14.2, which w a s ultimately developed during this validation study, and on additional relevant published and in-house data. 4. Definitions of key terms are set out in Annex 1. 1 INITIAL CONSIDERATIONS 5. The Comet assay is a method for measuring primary DNA strand breaks in eukaryotic cells.
    [Show full text]
  • Print Special Issue Flyer
    IMPACT FACTOR 4.096 an Open Access Journal by MDPI Non-Coding RNA in Rare Genetic Diseases Guest Editor: Message from the Guest Editor Dr. Tiziana Bachetti The vast majority of the genome produces transcripts that 1. Laboratorio di Neurobiologia are not translated into proteins and are generally defined dello Sviluppo, Università di as non-coding RNA (ncRNA); however, several studies have Genova, Genova, Italy 2. UOSD Laboratorio di Genetica revealed that they are not silent and that most of them e Genomica delle Malattie Rare, play a crucial role in regulating gene expression. IRCCS Giannina Gaslini, Genova, Italy This Special Issue focuses on the role of ncRNAs in the [email protected] molecular pathogenesis of rare diseases, particularly focusing on their dysregulation and possible use as targets for molecular diagnosis and developing therapies for this Deadline for manuscript class of disorders, which often lack specific treatments. submissions: 20 November 2021 mdpi.com/si/71848 SpeciaIslsue IMPACT FACTOR 4.096 an Open Access Journal by MDPI Editor-in-Chief Message from the Editor-in-Chief Prof. Dr. J. Peter W. Young Genes are central to our understanding of biology, and Department of Biology, University modern advances such as genomics and genome editing of York, Heslington, York YO10 have maintained genetics as a vibrant, diverse and 5DD, UK fastmoving field. There is a need for good quality, open access journals in this area, and the Genes team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.
    [Show full text]
  • FDA Genetic Toxicology Workshop How Many Doses of an Ames
    FDA Genetic Toxicology Workshop How many doses of an Ames- Positive/Mutagenic (DNA Reactive) Drug can be safely administered to Healthy Subjects? November 4, 2019 Enrollment of Healthy Subjects into First-In-Human phase 1 clinical trials • Healthy subjects are commonly enrolled into First-In-Human (FIH) phase 1 clinical trials of new drug candidates. • Studies are typically short (few days up to 2 weeks) • Treatment may be continuous or intermittent (e.g., washout period of 5 half- lives between doses) • Receive no benefits and potentially exposed to significant health risks • Patients will be enrolled in longer phase 2 and 3 trials • Advantages of conducting trials with healthy subjects include: • investigation of pharmacokinetics (PK)/bioavailability in the absence of other potentially confounding drugs • data not confounded by disease • Identification of maximum tolerated dose • reduction in patient exposure to ineffective drugs or doses • rapid subject accrual into a study 2 Supporting Nonclinical Pharmacology and Toxicology Studies • The supporting nonclinical data package for a new IND includes • pharmacology studies (in vitro and in vivo) • safety pharmacology studies (hERG, ECG, cardiovascular, and respiratory) • secondary pharmacology studies • TK/ADME studies (in vitro and in vivo) • 14- to 28-day toxicology studies in a rodent and non-rodent • standard battery of genetic toxicity studies (Ames bacterial reverse mutation assay, in vitro mammalian cell assay, and an in vivo micronucleus assay) • Toxicology studies are used to • select clinical doses that are adequately supported by the data • assist with clinical monitoring • Genetic toxicity studies are used for hazard identification • Cancer drugs are often presumed to be genotoxic and genetic toxicity studies are generally not required for clinical trials in cancer patients.
    [Show full text]
  • Toxicological Profile for Radon
    RADON 205 10. GLOSSARY Some terms in this glossary are generic and may not be used in this profile. Absorbed Dose, Chemical—The amount of a substance that is either absorbed into the body or placed in contact with the skin. For oral or inhalation routes, this is normally the product of the intake quantity and the uptake fraction divided by the body weight and, if appropriate, the time, expressed as mg/kg for a single intake or mg/kg/day for multiple intakes. For dermal exposure, this is the amount of material applied to the skin, and is normally divided by the body mass and expressed as mg/kg. Absorbed Dose, Radiation—The mean energy imparted to the irradiated medium, per unit mass, by ionizing radiation. Units: rad (rad), gray (Gy). Absorbed Fraction—A term used in internal dosimetry. It is that fraction of the photon energy (emitted within a specified volume of material) which is absorbed by the volume. The absorbed fraction depends on the source distribution, the photon energy, and the size, shape and composition of the volume. Absorption—The process by which a chemical penetrates the exchange boundaries of an organism after contact, or the process by which radiation imparts some or all of its energy to any material through which it passes. Self-Absorption—Absorption of radiation (emitted by radioactive atoms) by the material in which the atoms are located; in particular, the absorption of radiation within a sample being assayed. Absorption Coefficient—Fractional absorption of the energy of an unscattered beam of x- or gamma- radiation per unit thickness (linear absorption coefficient), per unit mass (mass absorption coefficient), or per atom (atomic absorption coefficient) of absorber, due to transfer of energy to the absorber.
    [Show full text]
  • S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use
    Guidance for Industry S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) June 2012 ICH Guidance for Industry S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Silver Spring, MD 20993-0002 Phone: 301-796-3400; Fax: 301-847-8714 [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication, Outreach and Development, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD 20852-1448 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (Tel) 800-835-4709 or 301-827-1800 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) June 2012 ICH Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION (1)....................................................................................................... 1 A. Objectives of the Guidance (1.1)...................................................................................................1
    [Show full text]